SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy

SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy

Long-term humoral immunity is mediated by short-lived plasma cells (replenished by memory B cells) and long-lived plasma cells. Their relative contributions are uncertain for immunity to SARS-CoV-2, especially given the widespread use of novel mRNA vaccines. Yet, this has far-reaching implications i...

Full description

Bibliographic Details
Main Authors: Liangjian Lu, Chang Yien Chan, Yi Yang Lim, Mya Than, Sharon Teo, Perry Y. W. Lau, Kar Hui Ng, Hui Kim Yap
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Vaccines
Subjects:
SARS-CoV-2
mRNA vaccines
long-lived plasma cells
Rituximab
Online Access:https://www.mdpi.com/2076-393X/11/12/1864

Similar Items

Similar Items